-
Please note that signing in with a Display Name has been removed. Email addresses must be used instead to login.
DEALS
Best deals, coupons, and promotional offers
12,077 topics in this forum
-
- 0 replies
- 374 views
-
- Tipontip
-
-
- 0 replies
- 263 views
-
- jackandjay
-
- 0 replies
- 558 views
-
- bujjulu
-
- 0 replies
- 251 views
-
- bujjulu
-
- 0 replies
- 375 views
-
- Tipontip
-
- 0 replies
- 435 views
-
- bujjulu
-
- 0 replies
- 407 views
-
- jackandjay
-
- 0 replies
- 2k views
-
- Guest
-
- 0 replies
- 401 views
-
- Tipontip
-
- 0 replies
- 397 views
-
- jackandjay
-
- 0 replies
- 394 views
-
- Tipontip
-
- 0 replies
- 341 views
-
- jackandjay
-
- 0 replies
- 394 views
-
- jackandjay
-
- 0 replies
- 363 views
-
- jackandjay
-
- 0 replies
- 310 views
-
- jackandjay
-
- 0 replies
- 1.7k views
-
- Sunnie
-
- 0 replies
- 402 views
-
- Ache
-
- 0 replies
- 449 views
-
- saami
-
- 0 replies
- 365 views
-
- bujjulu
-
- 0 replies
- 394 views
-
- bujjulu
-
- 0 replies
- 411 views
-
- saami
-
- 0 replies
- 283 views
-
- apptik
-
- 0 replies
- 395 views
-
- bujjulu
-
- 0 replies
- 455 views
-
- bujjulu
-
- 0 replies
- 465 views
-
- TellTheFolks
-
-
-
-
Popular Contributors
-
1
johnydanylee
391 -
2
DallasKarreballu
127 -
3
psycopk
102 -
4
Sucker
85 -
5
Android_Halwa
74
-
-
-
Most Contributions
-
-
-
Activity Stream
-
79
farmers are voluntarily coming forward to give their lands, Amaravati Second phase
Wait cheye bhaya, #musali_sintakaya_cheeketoda #musalodi_m0ddagudese vadu vachi reply estadu. arey @Sinthakai, ekkada chachavu ra bhaya waiting. -
2
Permanent cure for male-pattern baldness.Cosmo has released its Phase III trial results
https://www.cosmopharma.com/news/cosmo-announces-breakthrough-phase-iii-topline-results-from-scalp-1-and-scalp-2-for-clascoterone-5-solution-in-male-hair-loss-showing-up-to-539-relative-improvement-in-target-area-hair-count-vs-place Cosmo announces breakthrough Phase III Topline results from Scalp 1 and Scalp 2 for Clascoterone 5% Solution in male hair loss, showing up to 539% relative improvement in Target-Area Hair Count vs placebo; US and EU submissions are underway Ad hoc announcement pursuant to Art. 53 LR 1,465 patients were randomized into the two identical-in-design clinical studies Scalp 1 (NCT05910450) and Scalp 2 (NCT05914805) Both studies reached statistically significant endpoints in TAHC (Target-Area Hair Count), with one reaching 539% relative improvement to placebo and the second study reaching 168% relative improvement to placebo Positive safety profile demonstrated across both studies Positive safety profile demonstrated across both studie Largest Phase III program ever conducted for a Topical Treatment for Male Androgenetic Alopecia (AGA) First novel mechanism of action and first potential innovation in over 30 years in male hair loss Preparations are underway for parallel regulatory submissions in the United States and Europe -
-
-
1
-
